Sat, Feb 28, 2015, 2:38 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Sep 25, 2012 5:51 AM Flag

    Analysts on GHDX / Piper reiterates overweight rating

    Piper Jaffray reaffirmed their overweight rating on shares of Genomic Health (NASDAQ: GHDX) in a research note

    Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Genomic

    Health from an outperform rating to a neutral rating in a research note to investors on Friday, August 17th. They now have a $38.00 price target on the stock.

    Separately, analysts at Bank of America initiated coverage on shares of Genomic Health in a research note to investors on Thursday, August 16th. They set a buy rating and a $44.00 price
    target on the stock.

    Genomic Health last released its earnings data on Wednesday, August 8th. The company reported $0.06 EPS for thequarter, beating the Thomson Reuters consensus estimate of ($0.02) by $0.08. The company’s revenue for the quarterwas up 13.4% on a year-over-year basis.

    Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the development and global commercialization of genomic-based clinical laboratory services , which analyzes the underlying biology of cancer,allowing physicians and patients to make individualized treatment decisions

    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
30.40-0.65(-2.09%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.